Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2010 - 2018)

Neurocrine Biosciences' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $7.3 million for Q4 2018.

• Quarterly Non-Current Deffered Revenue fell 9.09% year-over-year to $7.3 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $7.3 million (down 9.09% YoY) and the FY2018 annual result came in at $7.3 million, down 9.09% from the prior year.
• Non-Current Deffered Revenue was $7.3 million for Q4 2018 at Neurocrine Biosciences, down from $7.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $16.8 million in Q1 2014 and bottomed at $1.5 million in Q4 2016.
• A 5-year average of $7.8 million and a median of $7.5 million in 2018 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2014 — Non-Current Deffered Revenue jumped 675.4% — and 2015, when it slumped 89.2%.
• Neurocrine Biosciences' Non-Current Deffered Revenue stood at $15.2 million in 2014, then fell by 28.11% to $10.9 million in 2015, then plunged by 86.58% to $1.5 million in 2016, then soared by 450.14% to $8.0 million in 2017, then decreased by 9.09% to $7.3 million in 2018.
• Business Quant data shows NBIX's Non-Current Deffered Revenue at $7.3 million in Q4 2018, $7.5 million in Q3 2018, and $5.3 million in Q2 2018.